Ruth Venning, MBA, IRC

Executive Director, Investor Relations and ESG, Horizon Therapeutics

Ruth Venning is executive director of Investor Relations and ESG for Horizon Therapeutics plc, a $26 billion biopharmaceutical company specializing in medicines for rare, autoimmune and severe inflammatory diseases. In addition to liaising with the investment community and other investor relations (IR) responsibilities, she is responsible Horizon’s ESG program, which she established. Before joining Horizon in May 2017, Venning was director of Investor Relations for Hospira, Inc., a generic injectable pharmaceutical and medical device company, where she worked from 2006 until the company was acquired by Pfizer Inc. in 2015. Before Hospira, she served in IR roles at Telephone and Data Systems, Inc. and United Airlines, and prior to that, she was with Calamos Asset Management, a Chicago-area investment management firm. Venning began her career in international relations, working primarily for the Japanese government in Japan.

Venning holds an MBA in Finance from Lake Forest Graduate School of Management, a master’s degree in Integrated Marketing Communications (IMC) from Northwestern University’s Medill School of Journalism, Media, Integrated Marketing Communications, and a bachelor’s degree in Japanese Studies from Earlham College. She received her Investor Relations Certification (IRC) in 2019.

Venning served on the NIRI Board of Directors from 2018 to 2023 and was Chair from 2020 to 2021. She currently serves as a director on the Chicago chapter Board. She is also a member of the National Association of Corporate Directors (NACD) and Women in Bio. From 2016 to 2018, she served as an adjunct instructor at Northwestern University’s IMC, where her teaching included graduate-level courses in Investor Relations.